Article info
PDFA difficult case
Grey matter abnormality in progressive multifocal leucoencephalopathy
- Correspondence to Christopher Yuki Itoh, Department of Neurology, University of California Davis School of Medicine, Sacramento, CA 95817, USA; citoh{at}ucdavis.edu
Citation
Grey matter abnormality in progressive multifocal leucoencephalopathy
Publication history
- Accepted February 3, 2021
- First published March 30, 2021.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Natalizumab - induced PML: can the beast be tamed
- MRI pattern in asymptomatic natalizumab - associated PML
- Multiple sclerosis reactivation postfingolimod cessation: Is it IRIS
- Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis
- Do CCR5 antagonists improve the overall survival of patients with AIDS - related progressive multifocal leucoencephalopathy
- Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis
- MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
- 4CPS-060 Prescription analysis of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in a third level hospital
- Concomitant progressive multifocal leucoencephalopathy and primary central nervous system lymphoma expressing JC virus oncogenic protein, large T antigen
- Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis